Education
About Us
Working with TipRanks
Follow Us
Verici Dx Plc (GB:VRCI)
LSE:VRCI
VRCI Stock Chart & Stats
0.72p
0.25p(4.35%)
At close: 4:00 PM EST
0.72p
0.25p(4.35%)
Day’s Range― - ―
52-Week Range0.47p - 3.75p
Previous CloseN/A
Volume9.63K
Average Volume (3M)6.85M
Market Cap
£9.46M
Enterprise Value12.56M
Total Cash (Recent Filing)£467.00K
Total Debt (Recent Filing)£282.00K
Price to Earnings (P/E)―
Beta-1.80
Next Earnings
Apr 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,513,394,200
10 Day Avg. Volume9,044,876
30 Day Avg. Volume6,845,005
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)2.15
Price to Sales (P/S)3.38
P/FCF Ratio-1.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetA strong equity position and low leverage give Verici durable financial flexibility to fund commercial expansion, clinical validation and operating losses over multiple quarters without immediate insolvency risk. This conservative capital structure supports longer-term strategic initiatives and resilience to cyclical shocks.
Operational And Regulatory CredentialsSuccessful CAP and ISO 27001 audits plus expansion agreements and board appointments materially strengthen lab quality, data security and governance. These durable credentials improve credibility with transplant centers, payers and partners, lowering barriers to adoption and enabling steadier commercial traction over months to years.
Recent Revenue GrowthReported year-over-year revenue increases indicate initial market uptake of Tutivia and Clarava. Sustained top-line growth over several quarters would enhance scale economics for the testing lab, spread fixed costs and improve the path to profitability by leveraging existing infrastructure and commercial channels.
Bears Say
Ongoing Net LossesPersistent negative EBIT and net losses mean the company is not yet generating operating profitability, pressuring returns and limiting reinvestment capacity. Over a multi-quarter horizon, sustained losses can force strategic trade-offs, slower commercial expansion or repeated external financing, diluting shareholder value.
Negative Operating Cash FlowNegative operating and free cash flow with reliance on financing indicates the business needs external capital to fund operations. This raises execution risk: future dilution or debt, constrained investment in sales/validation, and potential limits on scaling lab capacity during the crucial adoption period.
Dependence On Adoption And ReimbursementRevenue is structurally tied to clinician adoption and payer reimbursement, both slow and evidence-driven processes. Failure or delay in securing broad reimbursement or clinician uptake can cap test volumes and revenues for many quarters, making growth and margin improvement contingent on durable commercial and policy wins.
Verici Dx Plc News
VRCI FAQ
What was Verici Dx Plc’s price range in the past 12 months?
Verici Dx Plc lowest share price was 0.47p and its highest was 3.75p in the past 12 months.
What is Verici Dx Plc’s market cap?
Verici Dx Plc’s market cap is £9.46M.
When is Verici Dx Plc’s upcoming earnings report date?
Verici Dx Plc’s upcoming earnings report date is Apr 15, 2026 which is in 52 days.
How were Verici Dx Plc’s earnings last quarter?
Currently, no data Available
Is Verici Dx Plc overvalued?
According to Wall Street analysts Verici Dx Plc’s price is currently Overvalued.
Does Verici Dx Plc pay dividends?
Verici Dx Plc does not currently pay dividends.
What is Verici Dx Plc’s EPS estimate?
Verici Dx Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Verici Dx Plc have?
Verici Dx Plc has 1,513,394,200 shares outstanding.
What happened to Verici Dx Plc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Verici Dx Plc?
Currently, no hedge funds are holding shares in GB:VRCI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Verici Dx Plc
Verici Dx plc, an immuno-diagnostics development company, focuses on the kidney transplantation market. The company develops prognostic and diagnostic tests for kidney transplant patients. Its in-development tests include Clarava, a pre-transplant prognosis test for the risk of early acute rejection; Tuteva, a post-transplant test that focuses on acute cellular rejection; and Protega, a liquid biopsy that aims to predict the risk of fibrosis and long-term graft failure. The company was incorporated in 2020 and is based in Penarth, the United Kingdom.
Technical Analysis
EKF Diagnostics Holdings
―
Genedrive
―
Oxford BioDynamics
―
Renalytix
―
Abingdon Health PLC
―
Options Prices
Currently, No data available
---